Postoperative radiotherapy versus no postoperative radiotherapy in patients with completely resected non-small-cell lung cancer and proven mediastinal N2 involvement (Lung ART, IFCT 0503): an open-label, randomised, phase 3 trial

医学 肺癌 癌症 放射治疗 临床试验 呼吸道疾病 外科 随机对照试验 流行病学 入射(几何) 肺病 梅德林 普通外科 妇科 疾病
作者
Cecile Le Pechoux,Nicolas Pourel,Fabrice Barlési,D. Lerouge,D. Antoni,Bruno Lamezec,Ursula Nestle,Pierre Boisselier,Eric Dansin,Amaury Paumier,Karine Peignaux,François Thillays,Gérard Zalcman,Jeannick Madelaine,Eric Pichon,Anne Larrouy,A. Lavolé,Delphine Argo-Leignel,Marc Derollez,Corinne Faivre Finn
出处
期刊:Lancet Oncology [Elsevier BV]
卷期号:23 (1): 104-114 被引量:289
标识
DOI:10.1016/s1470-2045(21)00606-9
摘要

In patients with non-small-cell lung cancer (NSCLC), the use of postoperative radiotherapy (PORT) has been controversial since 1998, because of one meta-analysis showing a deleterious effect on survival in patients with pN0 and pN1, but with an unclear effect in patients with pN2 NSCLC. Because many changes have occurred in the management of patients with NSCLC, the role of three-dimensional (3D) conformal PORT warrants further investigation in patients with stage IIIAN2 NSCLC. The aim of this study was to establish whether PORT should be part of their standard treatment.Lung ART is an open-label, randomised, phase 3, superiority trial comparing mediastinal PORT to no PORT in patients with NSCLC with complete resection, nodal exploration, and cytologically or histologically proven N2 involvement. Previous neoadjuvant or adjuvant chemotherapy was allowed. Patients aged 18 years or older, with an WHO performance status of 0-2, were recruited from 64 hospitals and cancer centres in five countries (France, UK, Germany, Switzerland, and Belgium). Patients were randomly assigned (1:1) to either the PORT or no PORT (control) groups via a web randomisation system, and minimisation factors were the institution, administration of chemotherapy, number of mediastinal lymph node stations involved, histology, and use of pre-treatment PET scan. Patients received PORT at a dose of 54 Gy in 27 or 30 daily fractions, on five consecutive days a week. Three dimensional conformal radiotherapy was mandatory, and intensity-modulated radiotherapy was permitted in centres with expertise. The primary endpoint was disease-free survival, analysed by intention to treat at 3 years; patients from the PORT group who did not receive radiotherapy and patients from the control group with no follow-up were excluded from the safety analyses. This trial is now closed. This trial is registered with ClinicalTrials.gov number, NCT00410683.Between Aug 7, 2007, and July 17, 2018, 501 patients, predominantly staged with 18F-fluorodeoxyglucose (18F-FDG) PET (456 [91%]; 232 (92%) in the PORT group and 224 (90%) in the control group), were enrolled and randomly assigned to receive PORT (252 patients) or no PORT (249 patients). At the cutoff date of May 31, 2019, median follow-up was 4·8 years (IQR 2·9-7·0). 3-year disease-free survival was 47% (95% CI 40-54) with PORT versus 44% (37-51) without PORT, and the median disease-free survival was 30·5 months (95% CI 24-49) in the PORT group and 22·8 months (17-37) in the control group (hazard ratio 0·86; 95% CI 0·68-1·08; p=0·18). The most common grade 3-4 adverse events were pneumonitis (13 [5%] of 241 patients in the PORT group vs one [<1%] of 246 in the control group), lymphopenia (nine [4%] vs 0), and fatigue (six [3%] vs one [<1%]). Late-grade 3-4 cardiopulmonary toxicity was reported in 26 patients (11%) in the PORT group versus 12 (5%) in the control group. Two patients died from pneumonitis, partly related to radiotherapy and infection, and one patient died due to chemotherapy toxicity (sepsis) that was deemed to be treatment-related, all of whom were in the PORT group.Lung ART evaluated 3D conformal PORT after complete resection in patients who predominantly had been staged using (18F-FDG PET-CT and received neoadjuvant or adjuvant chemotherapy. 3-year disease-free survival was higher than expected in both groups, but PORT was not associated with an increased disease-free survival compared with no PORT. Conformal PORT cannot be recommended as the standard of care in patients with stage IIIAN2 NSCLC.French National Cancer Institute, Programme Hospitalier de Recherche Clinique from the French Health Ministry, Gustave Roussy, Cancer Research UK, Swiss State Secretary for Education, Research, and Innovation, Swiss Cancer Research Foundation, Swiss Cancer League.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Orange的应助被痴情志浩采纳,获得10
刚刚
我是谁的应助被zjw采纳,获得30
1秒前
昭昭完成签到,获得积分10
1秒前
张兵完成签到,获得积分10
1秒前
1秒前
1秒前
2秒前
2秒前
JJ完成签到 ,获得积分10
2秒前
ACMI发布了新的文献求助10
2秒前
2秒前
2秒前
01完成签到,获得积分10
3秒前
於菟完成签到 ,获得积分10
3秒前
直率柠檬发布了新的文献求助10
3秒前
小木子完成签到,获得积分10
3秒前
安靖完成签到,获得积分10
4秒前
4秒前
4秒前
情怀的应助被机灵的大白菜采纳,获得10
4秒前
pp完成签到,获得积分10
5秒前
终梦的应助被alone采纳,获得10
5秒前
6秒前
6秒前
xuan完成签到,获得积分10
6秒前
7秒前
ASYHJM完成签到,获得积分10
7秒前
Firsterchao发布了新的文献求助10
7秒前
我是谁的应助被朱雀采纳,获得30
7秒前
meow123完成签到 ,获得积分10
7秒前
王sy完成签到 ,获得积分10
7秒前
112我的完成签到,获得积分10
7秒前
水月完成签到,获得积分10
7秒前
8秒前
smh发布了新的文献求助10
8秒前
小鱼爱吃肉的应助被fortuna采纳,获得10
9秒前
9秒前
共享精神的应助被木木采纳,获得10
9秒前
地雷完成签到 ,获得积分10
9秒前
浪漫完成签到,获得积分10
10秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8160268
求助须知:如何正确求助?哪些是违规求助? 9555328
关于积分的说明 21727231
捐赠科研通 7750062
什么是DOI,文献DOI怎么找? 3427353
关于科研通互助平台的介绍 2552391
邀请新用户注册赠送积分活动 2471707